EP Patent

EP3662899A1 — Apixaban formulations

Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2020-06-10 · 6y expired

What this patent protects

The present invention provides tablets comprising a composition comprising crystalline apixaban particles having a mean particle size equal to or less than about 85 µm and a D<sub>90</sub>equal to or less than 85 µm and further comprising a pharmaceutically acceptable…

USPTO Abstract

The present invention provides tablets comprising a composition comprising crystalline apixaban particles having a mean particle size equal to or less than about 85 µm and a D<sub>90</sub>equal to or less than 85 µm and further comprising a pharmaceutically acceptable diluent or carrier as well as processes for producing the same.

Drugs covered by this patent

Patent Metadata

Patent number
EP3662899A1
Jurisdiction
EP
Classification
—
Expires
2020-06-10
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Holdings Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.